Marshall Wace’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-12,000
Closed -$345K – 2719
2023
Q4
$345K Hold
12,000
– – ﹤0.01% 1846
2023
Q3
$398K Sell
12,000
-46,500
-79% -$1.64M ﹤0.01% 1789
2023
Q2
$2.15M Sell
58,500
-175,100
-75% -$6.82M ﹤0.01% 1371
2023
Q1
$9.5M Buy
233,600
+138,300
+145% +$5.97M 0.02% 732
2022
Q4
$4.88M Sell
95,300
-259,900
-73% -$12.5M 0.01% 1203
2022
Q3
$15.5M Buy
355,200
+226,800
+177% +$11M 0.03% 587
2022
Q2
$6.73M Buy
128,400
+96,400
+301% +$4.91M 0.01% 1143
2022
Q1
$1.66M Sell
32,000
-208,100
-87% -$10.8M ﹤0.01% 2172
2021
Q4
$14.2M Buy
+240,100
New +$11.9M 0.03% 640

Other funds holding PFE

Marshall Wace's PFE Position: Q3 2026 in Review

Marshall Wace increased its Pfizer (PFE) stake by 372% in Q3 2026, buying an estimated $79.5M and bringing the position to 3,790,528 shares worth $108M. The position accounts for 0.09% of the portfolio, ranked #173.

Marshall Wace first reported a position in PFE in Q1 2014 and has held it in 44 quarters since. The position peaked at $452M in Q1 2026. 2,894 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Marshall Wace held 3,790,528 shares of Pfizer worth $108M as of Q3 2026.
  • Marshall Wace bought 2,988,132 Pfizer shares in Q3 2026, an estimated $79.5M.
  • Pfizer made up 0.09% of Marshall Wace's portfolio in Q3 2026, its #173 holding.
  • Marshall Wace first reported a position in Pfizer in Q1 2014 and has held it in 44 quarters since.
  • Marshall Wace's Pfizer position peaked at $452M in Q1 2026.
  • 2,894 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.